Parallax Volatility Advisers
VIR icon

Parallax Volatility Advisers’s Vir Biotechnology VIR Stock Holding History

Parallax Volatility Advisers’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4
Closed -$100 – 2893
2023
Q1 		$93 Buy
+4
New +$102 ﹤0.01% 2637
2022
Q1 		– Sell
-37,690
Closed -$1.58M – 3454
2021
Q4 		$1.58M Buy
+37,690
New +$1.48M ﹤0.01% 1725
2021
Q1 		– Sell
-187
Closed -$5K – 3678
2020
Q4 		$5K Buy
+187
New +$6.08K ﹤0.01% 3228

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parallax Volatility Advisers's VIR Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 4 shares — an estimated $100 sold.

Parallax Volatility Advisers first reported a position in VIR in Q4 2020 and held it in 3 quarters. The position peaked at $1.58M in Q4 2021. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

  • Parallax Volatility Advisers reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 4 Vir Biotechnology shares in Q2 2023, an estimated $100.
  • Parallax Volatility Advisers first reported a position in Vir Biotechnology in Q4 2020 and held it in 3 quarters.
  • Parallax Volatility Advisers's Vir Biotechnology position peaked at $1.58M in Q4 2021.
  • 226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.